QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
NASDAQ:NVCR

NovoCure Competitors

$173.13
+0.18 (+0.10 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$165.49
Now: $173.13
$177.77
50-Day Range
$156.57
MA: $174.02
$190.17
52-Week Range
$53.40
Now: $173.13
$194.75
Volume813,602 shs
Average Volume627,701 shs
Market Capitalization$17.62 billion
P/E Ratio911.26
Dividend YieldN/A
Beta1.29

Competitors

NovoCure (NASDAQ:NVCR) Vs. BSX, BAX, DXCM, RMD, TFX, and PODD

Should you be buying NVCR stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to NovoCure, including Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), and Insulet (PODD).

NovoCure (NASDAQ:NVCR) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for NovoCure and Boston Scientific, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NovoCure14402.33
Boston Scientific041622.91

NovoCure presently has a consensus target price of $126.00, indicating a potential downside of 27.22%. Boston Scientific has a consensus target price of $42.7826, indicating a potential upside of 8.23%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than NovoCure.

Profitability

This table compares NovoCure and Boston Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoCure4.26%7.40%3.94%
Boston Scientific36.59%11.77%5.57%

Insider & Institutional Ownership

71.1% of NovoCure shares are owned by institutional investors. Comparatively, 90.7% of Boston Scientific shares are owned by institutional investors. 5.1% of NovoCure shares are owned by company insiders. Comparatively, 0.7% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares NovoCure and Boston Scientific's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoCure$351.32 million50.17$-7,230,000.00($0.07)-2,473.29
Boston Scientific$10.74 billion5.27$4.70 billion$1.5825.02

Boston Scientific has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

NovoCure has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Summary

Boston Scientific beats NovoCure on 11 of the 15 factors compared between the two stocks.

NovoCure (NASDAQ:NVCR) and Baxter International (NYSE:BAX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Insider & Institutional Ownership

71.1% of NovoCure shares are owned by institutional investors. Comparatively, 82.9% of Baxter International shares are owned by institutional investors. 5.1% of NovoCure shares are owned by company insiders. Comparatively, 0.1% of Baxter International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for NovoCure and Baxter International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NovoCure14402.33
Baxter International061002.63

NovoCure presently has a consensus target price of $126.00, indicating a potential downside of 27.22%. Baxter International has a consensus target price of $92.2667, indicating a potential upside of 17.52%. Given Baxter International's stronger consensus rating and higher possible upside, analysts clearly believe Baxter International is more favorable than NovoCure.

Profitability

This table compares NovoCure and Baxter International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoCure4.26%7.40%3.94%
Baxter International7.90%20.81%8.78%

Volatility & Risk

NovoCure has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Earnings & Valuation

This table compares NovoCure and Baxter International's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoCure$351.32 million50.17$-7,230,000.00($0.07)-2,473.29
Baxter International$11.36 billion3.49$1.00 billion$3.3123.72

Baxter International has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

Summary

Baxter International beats NovoCure on 10 of the 14 factors compared between the two stocks.

NovoCure (NASDAQ:NVCR) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Insider and Institutional Ownership

71.1% of NovoCure shares are owned by institutional investors. Comparatively, 94.1% of DexCom shares are owned by institutional investors. 5.1% of NovoCure shares are owned by company insiders. Comparatively, 0.7% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for NovoCure and DexCom, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NovoCure14402.33
DexCom121402.76

NovoCure currently has a consensus target price of $126.00, indicating a potential downside of 27.22%. DexCom has a consensus target price of $430.3750, indicating a potential upside of 6.10%. Given DexCom's stronger consensus rating and higher possible upside, analysts plainly believe DexCom is more favorable than NovoCure.

Profitability

This table compares NovoCure and DexCom's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoCure4.26%7.40%3.94%
DexCom12.69%27.29%10.45%

Volatility & Risk

NovoCure has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, DexCom has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Earnings and Valuation

This table compares NovoCure and DexCom's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoCure$351.32 million50.17$-7,230,000.00($0.07)-2,473.29
DexCom$1.48 billion26.43$101.10 million$1.84220.46

DexCom has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Summary

DexCom beats NovoCure on 10 of the 14 factors compared between the two stocks.

NovoCure (NASDAQ:NVCR) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Insider and Institutional Ownership

71.1% of NovoCure shares are owned by institutional investors. Comparatively, 68.6% of ResMed shares are owned by institutional investors. 5.1% of NovoCure shares are owned by company insiders. Comparatively, 1.3% of ResMed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for NovoCure and ResMed, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NovoCure14402.33
ResMed05402.44

NovoCure currently has a consensus target price of $126.00, indicating a potential downside of 27.22%. ResMed has a consensus target price of $189.40, indicating a potential downside of 5.76%. Given ResMed's stronger consensus rating and higher possible upside, analysts plainly believe ResMed is more favorable than NovoCure.

Profitability

This table compares NovoCure and ResMed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoCure4.26%7.40%3.94%
ResMed22.45%30.64%16.43%

Volatility & Risk

NovoCure has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, ResMed has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.

Earnings and Valuation

This table compares NovoCure and ResMed's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoCure$351.32 million50.17$-7,230,000.00($0.07)-2,473.29
ResMed$2.96 billion9.89$621.67 million$4.7642.22

ResMed has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Summary

ResMed beats NovoCure on 8 of the 13 factors compared between the two stocks.

NovoCure (NASDAQ:NVCR) and Teleflex (NYSE:TFX) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Insider and Institutional Ownership

71.1% of NovoCure shares are owned by institutional investors. Comparatively, 89.8% of Teleflex shares are owned by institutional investors. 5.1% of NovoCure shares are owned by company insiders. Comparatively, 2.2% of Teleflex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for NovoCure and Teleflex, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NovoCure14402.33
Teleflex01913.00

NovoCure currently has a consensus target price of $126.00, indicating a potential downside of 27.22%. Teleflex has a consensus target price of $421.2727, indicating a potential upside of 5.22%. Given Teleflex's stronger consensus rating and higher possible upside, analysts plainly believe Teleflex is more favorable than NovoCure.

Profitability

This table compares NovoCure and Teleflex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoCure4.26%7.40%3.94%
Teleflex14.66%16.33%7.66%

Volatility & Risk

NovoCure has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Teleflex has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Earnings and Valuation

This table compares NovoCure and Teleflex's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoCure$351.32 million50.17$-7,230,000.00($0.07)-2,473.29
Teleflex$2.60 billion7.18$461.47 million$11.1535.91

Teleflex has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Summary

Teleflex beats NovoCure on 11 of the 15 factors compared between the two stocks.

NovoCure (NASDAQ:NVCR) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Insider and Institutional Ownership

71.1% of NovoCure shares are owned by institutional investors. 5.1% of NovoCure shares are owned by company insiders. Comparatively, 1.1% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for NovoCure and Insulet, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NovoCure14402.33
Insulet113602.25

NovoCure currently has a consensus target price of $126.00, indicating a potential downside of 27.22%. Insulet has a consensus target price of $243.0556, indicating a potential downside of 7.36%. Given Insulet's higher possible upside, analysts plainly believe Insulet is more favorable than NovoCure.

Profitability

This table compares NovoCure and Insulet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoCure4.26%7.40%3.94%
Insulet3.33%8.94%2.07%

Volatility & Risk

NovoCure has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Insulet has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Earnings and Valuation

This table compares NovoCure and Insulet's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoCure$351.32 million50.17$-7,230,000.00($0.07)-2,473.29
Insulet$738.20 million23.43$11.60 million$0.191,380.84

Insulet has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Summary

NovoCure beats Insulet on 8 of the 14 factors compared between the two stocks.


NovoCure Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Boston Scientific logo
BSX
Boston Scientific
2.0$39.53+2.0%$56.60 billion$10.74 billion15.15Insider Selling
Baxter International logo
BAX
Baxter International
2.3$78.51+0.5%$39.66 billion$11.36 billion44.61
DexCom logo
DXCM
DexCom
1.7$405.64+0.3%$39.01 billion$1.48 billion167.62
ResMed logo
RMD
ResMed
1.4$200.97+0.4%$29.24 billion$2.96 billion43.13Insider Selling
Teleflex logo
TFX
Teleflex
2.0$400.39+1.3%$18.64 billion$2.60 billion51.53Upcoming Earnings
Insulet logo
PODD
Insulet
1.3$262.36+0.6%$17.30 billion$738.20 million596.29Earnings Announcement
Analyst Report
News Coverage
Abiomed logo
ABMD
Abiomed
1.5$323.78+0.6%$14.64 billion$840.88 million71.16
Penumbra logo
PEN
Penumbra
1.5$288.94+2.9%$10.49 billion$547.41 million-1,070.15Earnings Announcement
Analyst Report
News Coverage
Gap Down
Hill-Rom logo
HRC
Hill-Rom
2.2$108.02+1.4%$7.17 billion$2.88 billion32.54
Haemonetics logo
HAE
Haemonetics
1.6$130.62+1.0%$6.64 billion$988.48 million63.10
Globus Medical logo
GMED
Globus Medical
1.6$63.40+0.4%$6.26 billion$785.37 million68.91Analyst Revision
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.4$231.21+4.6%$6.23 billion$82.05 million-99.66Earnings Announcement
Analyst Report
News Coverage
Gap Down
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$70.24+1.6%$5.92 billion$1.52 billion104.84Earnings Announcement
Analyst Revision
Nevro logo
NVRO
Nevro
1.2$170.91+2.9%$5.88 billion$390.26 million-62.83News Coverage
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.6$91.30+0.5%$5.56 billion$362.30 million-112.71News Coverage
Inari Medical logo
NARI
Inari Medical
0.8$108.45+3.0%$5.28 billionN/A0.00Insider Selling
News Coverage
ICU Medical logo
ICUI
ICU Medical
1.3$219.54+1.2%$4.61 billion$1.27 billion58.08Upcoming Earnings
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.6$153.00+1.6%$4.42 billion$214.55 million-80.10Upcoming Earnings
Glaukos logo
GKOS
Glaukos
0.9$96.43+2.4%$4.34 billion$236.98 million-58.44Upcoming Earnings
Unusual Options Activity
SWAV
ShockWave Medical
1.4$126.04+3.4%$4.32 billion$42.93 million-62.40Earnings Announcement
Insider Selling
Analyst Revision
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$56.46+1.1%$3.14 billion$994.85 million-106.53News Coverage
Cantel Medical logo
CMD
Cantel Medical
1.3$73.36+0.0%$3.10 billion$1.02 billion87.33
NuVasive logo
NUVA
NuVasive
1.3$58.46+1.2%$3.00 billion$1.17 billion-265.73Upcoming Earnings
AtriCure logo
ATRC
AtriCure
1.5$62.41+0.3%$2.81 billion$230.81 million-54.27Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
Gap Up
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$12.01+2.7%$2.24 billion$4.11 million-8.83Upcoming Earnings
AXNX
Axonics Modulation Technologies
1.5$52.87+0.9%$2.10 billion$13.82 million-26.97Upcoming Earnings
News Coverage
LUNG
Pulmonx
0.7$55.00+1.3%$1.96 billion$32.60 million0.00Upcoming Earnings
News Coverage
SILK
Silk Road Medical
1.1$53.14+2.7%$1.80 billion$63.35 million-43.56Upcoming Earnings
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.5$42.29+2.2%$1.70 billion$236.54 million-64.07
Luminex logo
LMNX
Luminex
2.1$30.05+6.3%$1.40 billion$334.64 million77.05
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.4$19.29+0.1%$1.38 billion$88.02 million-47.05Upcoming Earnings
Alphatec logo
ATEC
Alphatec
0.8$16.46+2.2%$1.29 billion$113.43 million-14.96Analyst Downgrade
Atrion logo
ATRI
Atrion
1.1$656.80+4.0%$1.22 billion$155.07 million37.00News Coverage
Cerus logo
CERS
Cerus
1.5$6.72+0.7%$1.12 billion$74.65 million-17.23Upcoming Earnings
News Coverage
MDXG
MiMedx Group
0.0$10.03+5.0%$1.11 billion$299.26 million-10.67News Coverage
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.3$55.80+1.4%$1.09 billion$72.55 million-38.75Upcoming Earnings
Insider Selling
SIBN
SI-BONE
1.2$32.41+2.2%$1.05 billion$67.30 million-20.26
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.4$53.57+6.0%$1.04 billion$189.49 million-119.04Earnings Announcement
News Coverage
Gap Up
CryoLife logo
CRY
CryoLife
1.6$26.31+3.4%$1.02 billion$276.22 million-69.24
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$47.67+1.0%$969.70 million$117.23 million51.26Upcoming Earnings
Orthofix Medical logo
OFIX
Orthofix Medical
1.3$47.87+0.8%$925.52 million$459.95 million39.89Upcoming Earnings
News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$31.90+1.0%$808.41 millionN/A-14.05Earnings Announcement
Intersect ENT logo
XENT
Intersect ENT
1.2$24.21+0.5%$792.13 million$109.14 million-12.68Unusual Options Activity
News Coverage
AngioDynamics logo
ANGO
AngioDynamics
1.4$20.51+1.8%$778.64 million$264.16 million-4.59
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.85+4.9%$778.30 million$154.60 million-47.17Upcoming Earnings
Gap Down
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.48+0.9%$746.69 million$123.86 million74.68Upcoming Earnings
Surmodics logo
SRDX
Surmodics
1.5$51.70+3.3%$711.19 million$94.86 million646.25News Coverage
VAPO
Vapotherm
1.5$27.01+1.4%$693.10 million$48.10 million-12.86News Coverage
AFIB
Acutus Medical
1.5$21.59+2.3%$601.20 million$2.84 million0.00Upcoming Earnings
News Coverage
SeaSpine logo
SPNE
SeaSpine
1.3$20.30+5.1%$560.95 million$159.08 million-12.16Upcoming Earnings
News Coverage
This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.